Form 4 Filing for Adaptive Biotechnologies Corp

On April 6-8, 2026, Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp, executed a series of transactions involving the company's common stock. These transactions were conducted under a Rule 10b5-1 trading plan. Rubinstein acquired a total of 43,285 shares of common stock through option exercises at prices ranging from $7.27 to $12.14 per share. Concurrently, she disposed of 69,001 shares of common stock. The sales occurred at weighted average prices between $13.56 and $14.83, with individual sale prices ranging from $13.39 to $15.48. Following these transactions, Rubinstein's post-transaction holdings include 434,188 shares of common stock directly owned. Additionally, the filing details the exercise and disposal of stock options, with post-transaction shares owned following the exercise of options amounting to 37,553 and 391,658 shares, respectively, under different option grants.